Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-L1/CTLA4 BsAb (KN046) with Chemotherapy in Pancreatic Cancer
NCT04324307Phase 2Unknown
- Sponsor
- Changhai Hospital
- Start
- Nov 2019
- Primary completion
- Nov 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of erfonrilimab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Changhai Hospital. Status: unknown.
02
Drugs
erfonrilimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04324307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04324307.